Develops pain and nausea drugs for cancer and surgery patients.
Jun 2026Revenue $151M/yrExpenses $162M/yr
No trendCash runway ≈ 3.5 years from Jun 2026
Figures by year
When will Heron Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $151M and expenses $162M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $155M | $157M | −$2.54M |
| Dec 2024 | $144M | $156M | −$11.5M |
| Dec 2023 | $127M | $238M | −$111M |
| Dec 2022 | $108M | $282M | −$175M |
| Dec 2021 | $86.3M | $304M | −$218M |
| Dec 2020 | $88.6M | $317M | −$228M |
| Dec 2019 | $146M | $357M | −$211M |
| Dec 2018 | $77.5M | $261M | −$184M |
| Dec 2017 | $30.8M | $225M | −$195M |
| Dec 2016 | $1.28M | $172M | −$171M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.